home / stock / ncna / ncna quote
Last: | $2.7965 |
---|---|
Change Percent: | -2.91% |
Open: | $2.83 |
Close: | $2.7965 |
High: | $2.93 |
Low: | $2.7032 |
Volume: | 15,927 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.7965 | $2.83 | $2.7965 | $2.93 | $2.7032 | 15,927 | 07-05-2024 |
$2.7501 | $2.53 | $2.7501 | $2.8245 | $2.53 | 9,358 | 07-04-2024 |
$2.7501 | $2.53 | $2.7501 | $2.8245 | $2.53 | 9,358 | 07-03-2024 |
$2.57 | $2.74 | $2.57 | $2.77 | $2.57 | 6,344 | 07-02-2024 |
$2.77 | $2.7 | $2.77 | $2.77 | $2.67 | 5,029 | 07-01-2024 |
$2.55 | $2.76 | $2.55 | $2.7999 | $2.54 | 39,747 | 06-28-2024 |
$2.74 | $2.755 | $2.74 | $2.79 | $2.685 | 2,889 | 06-27-2024 |
$2.71 | $2.7862 | $2.71 | $2.8 | $2.65 | 19,281 | 06-26-2024 |
$2.755 | $2.85 | $2.755 | $2.95 | $2.755 | 21,773 | 06-25-2024 |
$2.955 | $2.97 | $2.955 | $3.07 | $2.8501 | 11,547 | 06-24-2024 |
$2.965 | $2.9 | $2.965 | $3 | $2.9 | 3,921 | 06-21-2024 |
$2.92 | $2.99 | $2.92 | $3.0399 | $2.92 | 4,936 | 06-20-2024 |
$2.96 | $2.955 | $2.96 | $2.9899 | $2.9232 | 3,166 | 06-19-2024 |
$2.96 | $2.955 | $2.96 | $2.9899 | $2.9232 | 3,166 | 06-18-2024 |
$2.99 | $2.95 | $2.99 | $3.06 | $2.9466 | 9,472 | 06-17-2024 |
$3 | $3.16 | $3 | $3.16 | $3 | 11,516 | 06-14-2024 |
$3.03 | $3.13 | $3.03 | $3.13 | $3.03 | 7,830 | 06-13-2024 |
$3.03 | $3.18 | $3.03 | $3.27 | $3.01 | 20,355 | 06-12-2024 |
$3.06 | $3.29 | $3.06 | $3.29 | $3.0305 | 2,872 | 06-11-2024 |
$3.15 | $3.1 | $3.15 | $3.25 | $3.06 | 17,938 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...